Contrave Weight Loss Medicine

Weight Loss Drug Contrave Now Approved by FDA

Contrave Weight Loss MedicineThe Food and Drug Administration (FDA) has finally approved the weight loss drug Contrave.

The approval has been a long awaited outcome. When an FDA advisory panel voted to recommend the drug in December 2010, FDA approval was expected to follow. Instead, the FDA rejected the drug in February 2011, with a request for additional studies to determine whether or not the benefits of using the weight loss drug outweighed the cardiovascular side effects.

The study results were submitted in November 2013. The decision was finally announced this month granting approval. It is expected to be available sometime later in the fall of this year for patients with a prescription.

(more…)

Read More

BELVIQ Weight Loss Drug Now Available in US Pharmacies

Belviq Weight Loss DrugNearly a year after the weight loss drug BELVIQ was officially approved by The Food and Drug Administration (FDA), it is now available to patients by prescription in US pharmacies.

BELVIQ (trade name for the drug compound lorcaserin hydrochloride) is the first weight loss drug approved by the FDA in 13 years. It is used for chronic weight management in adults with overweight or obesity as an addition to a reduced-calorie diet and exercise.

The launching of BELVIQ in the United States was delayed due to a pending review and final scheduling designation by the Drug Enforcement Agency (DEA). The DEA’s final ruling was issued in May 2013, removing the last obstacle for it’s market debut.

(more…)

Read More

FDA Approves Retail Availability of Qsymia Weight Loss Drug

Qsymia Weight Loss DrugThe weight loss drug Qsymia will soon be available at retail pharmacies following approval from the Food and Drug Administration for a change to the distribution options specified in the Risk Evaluation and Mitigation Strategy (REMS).

REMS are required by the FDA when drugs are potentially harmful, especially when used in ways other than intended. A REMS can include a Medication Guide, Patient Package Insert, a mandatory Pharmacist Consultation, or other elements to assure safe use.

When Qsymia was initially approved by the FDA in 2012, the REMS limited the sale of the drug to mail-order pharmacies to ensure women were given instructions on how to use the drug and to prevent pregnant women from taking the drug in order to reduce birth defects.

Now, retail pharmacies that go through a certification process will be able to provide Qsymia, in addition to the existing network of certified mail-order pharmacies.

(more…)

Read More

Weight Loss Medications

FDA Approves Two Medications for Long-Term Weight Control

Weight Loss MedicationsThe Food and Drug Administration (FDA) has approved two new weight loss drugs – marketed as Belviq and Qsymia – within the last 30 days. These are the first medications to be cleared by the FDA for marketing in the United States in 13 years.

According to FDA statements, these medications aim “to help obese and overweight Americans who have been unsuccessful in getting their weight under control with diet and exercise.”

The approval of these drugs will expand the treatment options available for the overweight and obese, but with modest weight loss and potential side effects, will consumers actually use them?

(more…)

Read More

Orexigen Therapeutics Weight Loss Drug Contrave

Weight Loss Drug Contrave Rejected by FDA

Orexigen TherapeuticsThe FDA ruled against approving the weight loss drug Contrave in a decision that surprised many. A positive vote was expected, since an advisory panel had recommended approving the drug by a vote of 13-to-7 in December.

As this decision shows, the FDA is not required to follow the advice of its expert panels. Rather, the FDA requested additional clinical trials to determine whether or not the benefits of using the weight loss drug outweighed the cardiovascular side effects.

(more…)

Read More

Contrave Obesity Drug

Orexigen Asks FDA for Approval of Contrave Weight Loss Drug

Contrave Obesity DrugFollowing successful results in clinical trials with its potential weight loss drug Contrave, Orexigen Therapeutics has taken the next step for market approval and submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA).

Contrave is now one of several obesity drugs that are currently awaiting FDA approval. Rather than affecting food digestion and blocking fat absorption, Contrave acts on the central nervous system to reduce hunger, increase energy expenditure, and negatively alter the palpability of sweets.

If approval of the NDA is granted, the company will legally be able to sell and market Contrave in the United States as a weight loss therapy, although consumer use will require a prescription from a medical professional.

(more…)

Read More

Peptide Injection for Obesity

New Miracle Drug to Cure Obesity?

Peptide Injection for ObesityRichard DiMarchi and colleagues are taking a shot to eliminate obesity – literally. The researchers have found that a single injection of a new drug offers great potential as a pharmocological treatment for obesity. The use of drugs to induce weight loss is not new, but current methods have limited effectiveness and health risks.

By combining two natural peptide hormones, glucagon and GLP-1, into a single drug, researchers have demonstrated that it is possible to reduce weight and fat mass in rodents without any apparent side effects. After a single injection, the mice had a 25% decrease in body weight and a 42% decrease in fat mass after one week. Repeated treatment resulted in greater effects.

(more…)

Read More